Executive Summary
NASA modified a $109M cost-plus-fixed-fee delivery order to Caltech (JPL operator) for space science R&D including EMIT mineral dust investigation, with $90M outlayed and $16M unexercised options through 2028. Neutral equity signal due to nonprofit recipient limits direct investment impact. Highlights steady federal FFRDC funding stability amid long-term NASA commitments.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior Significant Contract Modifications ($10M+) digest from March 15, 2026.
Risk Flags (1)
- Execution [MEDIUM RISK]▼
Full $109M obligation and $125M ceiling depend on future NASA task orders over 2.5-year remaining period to 2028.
Opportunities (1)
- ◆
$16M unexercised options plus potential additional NASA task orders via JPL FFRDC sponsorship through 2028.
Sector Themes (1)
- ◆
10-year $109M+ delivery order underscores non-competed, long-duration support for space science R&D under NAICS 541715.
Watch List (1)
- 👁
{"entity"=>"Caltech/JPL NASA Task Orders", "reason"=>"Key to realizing remaining $19M obligation ceiling and future awards through 2028.", "trigger"=>"New orders or option exercises exceeding $125M ceiling"}
Get daily alerts with 1 risk alerts, 1 opportunities and full AI analysis of all 1 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: Significant Contract Modifications ($10M+)
🇺🇸 More from United States
View all →May 27, 2026
US Pre-Market SEC Filings Roundup — May 27, 2026
US Pre-Market SEC Filings Roundup
May 27, 2026
S&P 500 Technology Sector SEC Filings — May 27, 2026
S&P 500 Technology Sector SEC Filings
May 27, 2026
Orphan Drug Approvals — May 27, 2026
Orphan Drug Approvals
May 27, 2026
Big Pharma Approvals — May 27, 2026
Big Pharma Approvals